Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 29;75(11):3311–3318. doi: 10.1093/jac/dkaa309

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 2. — Proportion of people on ART including InSTIs in England between 2010 and 2015. The data were estimated from ART prescribing data from NHS England and are stratified by the PHE regions of London, Midlands & East of England (M&E), North of England and South of England. Data for London in 2015 do not include figures for the month of December. Hospitals in the former North West Strategic Health Authority (SHA) preferred to use raltegravir over bPIs as the third agent for a significant portion of the survey period. Figures may include a source of overestimation as raltegravir was used as first-line post-exposure prophylaxis following sexual exposure (PEPSE). NA, data not available.